Member Info for flava

MAJWandCo. We all know what happened with RCGH; it was pumped by online crooks through a Google Ads campaign.

We're dealing with two different companies here, and I don't think any poster here will make a difference in the SP movements. Pi's buying is based on the company's undervalued position, as seen in the Monday RNS, and nothing has changed here apart from the reversal play.

Prices are building back up 39p to buy now.

There's too much pressure on the market.

it's about to bounce back.

Market Makers are overwhelmed, and there's no cheap stock left in reserve.

The price action is currently in a strong uptrend, with a rapid move from the 40s to the 50s.

One more top-up done.

Break out at 58p. Once we do, all bets are off the table. Who's willing to hold for the GOLD?

If anyone have access to L2 then you can see all buys lined up. 44p, 45p and 50p

Don't give your shares for cheap. GLA

Stupid autocorrect *late print

latest profits

I'm saying that while small retail investors are buying in small amounts, the big players are buying in bulk behind the scenes. Just look at the latest profits that have just appeared.

10:04:46 43.9677 30,000 13.19k

Don't forget that the SP dropped in December 2021 from 165p due to the FDA requiring additional data to facilitate the 510k approval.

July 2023 - RUA Vascular and the FDA reached an agreement on the regulatory pathway for the company's polymerically sealed vascular grafts. This agreement is expected to expedite the approval process for the grafts. Additionally, RUA Vascular also signed a global distribution agreement in July 2023, which will provide the company with access to a global market for its products.

November 2023 - RUA Vascular has now reached the stage of being fully prepared to commence the regulatory testing regime agreed with the FDA through the pre-submission process to achieve 510k approval.

These two developments are significant milestones for RUA Vascular and bring the company closer to commercialising its innovative vascular grafts.

We're now back to normal and 150p is still cheap.

RUA revolutionary heart valve technology up for sale and releasing industry data. This game-changer could disrupt the $10 billion annual heart valve market , currently dominated by Edwards and Medtronic.

It is indeed significant that RUA has made its heart valve technology available for sale. This is a clear indication that the company is confident in the potential of its product to disrupt the heart valve market, which is currently dominated by two major players, Edwards and Medtronic. The fact that RUA has produced a data pack for the industry suggests that it is actively seeking partnerships or licensing deals with potential buyers. This could be a very lucrative opportunity for RUA, as the heart valve market is worth an estimated $10 billion annually.

Edwards and Medtronic are likely to be watching RUA's progress with great interest. Both companies have a strong track record of innovation in the heart valve market, and they are not likely to cede their leadership position without a fight. However, RUA's disruptive technology could pose a serious threat to their dominance. If RUA is able to successfully commercialise its heart valve, it could capture a significant share of the market and force Edwards and Medtronic to adapt.

The outcome of this competition could have a major impact on the future of the heart valve market. It will be interesting to see how Edwards and Medtronic respond to RUA's challenge.

150p if the volume continues. The company also mentioned that RUA Vascular will be exploited by seeking third-party funding while retaining an interest in the project. There is plenty of upside.

Gordon, nice one! Glad you bought it for cheap. For me, we're in a reversal play, and we may touch the 150s sometime this week. GLA!

These traders from yesterday, nearly £40,000 buys over 54p and highs of 58.40p

21-Nov-23 11:28:58 58.40 17,102 Unknown* 48.00 51.00 9,988 O

21-Nov-23 11:28:35 58.40 13,839 Unknown* 48.00 52.00 8,082 O

21-Nov-23 11:25:31 55.1675 15,000 Unknown* 48.00 52.00 8,275

21-Nov-23 11:17:40 54.70 20,000 Unknown* 48.00 50.00 10.94k

Nice one if anyone manages to buy cheap shares. Yesterday, there were big buys at 58.40p.

Very cheap entry for big rewards here.

Nice tree shake, MMs raiding stop losses for cheap shares.

Director Mr. Lachlan Arthur Smith bought at 54.17p December last year.

This is a positive announcement for RUA Life Sciences, as it indicates that the company is in a better financial position than previously thought. The change in strategy has reduced the company's need for future funding, while recent developments at both RUA Contract Manufacture and RUA Structural Heart have provided opportunities for the company to reach profitability and generate cash flow in a shorter timeframe. This is good news for investors, as it means that the company is more likely to be successful in the long run.

Here is a more detailed explanation of the key points in the announcement:

Change in strategy: The company has changed its strategy to focus on its two most promising businesses, RUA Contract Manufacture and RUA Structural Heart. This has reduced the company's need to invest in other areas, which has freed up cash flow.

Recent developments at RUA Contract Manufacture: RUA Contract Manufacture has recently secured a number of new contracts, which has increased its revenue and profitability.

Recent developments at RUA Structural Heart: RUA Structural Heart has made progress in the development of its lead product, which is expected to be launched in the market in the near future. This product has the potential to be a major source of revenue for the company.

Overall, this is a positive announcement for RUA Life Sciences. The company is in a better financial position than previously thought, and it has a clear path to profitability. Investors should be optimistic about the company's future prospects.

Please review the transcript from the company's RNS announcement from two days ago 👇

"We believe that the Vascular project has very attractive risk adjusted returns on the additional investment required to achieve regulatory approval. The limiting factor however is the cost of capital placed upon RUA because of the depressed share price. Not only would dilution relate to the interest in the Vascular project but the substantial upside potential from both RUA Contract Manufacture and RUA Structural Heart would be limited for current shareholders. The investment in RUA Vascular will be exploited by seeking third party funding whilst retaining an interest in the project.

The change in strategy has dramatically reduced the future funding requirements of RUA and the recent developments at both RUA Contract Manufacture and RUA Structural Heart have provided opportunities and a pathway for the Group to reach profitability and cash generation in a significantly shorter timeframe."

Bankruptstock, I'm happy to hold my position in this stock and don't worry about me instructing my broker to sell. I have already set up a sell limit order at 250p myself. This is a feature of many online brokerage accounts that allows you to set a price at which your shares will automatically be sold if the market price reaches that level. lol

I'm sure everyone knows that you're not happy with this rise. Maybe someday if you invest and make money rather than trolling non-stop, then you might make some money.